TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04456855

Intervention type: PROCEDURE
Intervention: Locoregional surgery
Description: Patients had pathologically confirmed operable stage IV breast infiltrating carcinoma at initial presentation, and had locoregional surgery for the breast cancer.
Study: NCT00947687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR003
Description: Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
Study: NCT04451772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Upadacitinib
Description: Film-coated tablet; Oral
Study: NCT00947687

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03173183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: genuine regional Rhizoma Atractylodis (Maozhu granule)
Description: Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: genuine regional Rhizoma Atractylodis (Maozhu granule)
Description: Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: genuine regional Rhizoma Atractylodis (Maozhu granule)
Description: Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd.
Study: NCT05764707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Patients will received 1000mg of intravenous acetaminophen within 30 minutes of skin closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will received 1000mg of normal saline within 30 minutes of skin closure.
Study: NCT02796261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine
Description: Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 week on, 1 week off schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Lomustine 90 mg/m2 administered orally once every 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Lomustine 110 mg/m2 administered orally once every 6 weeks
Study: NCT04380272

Intervention type: DIAGNOSTIC_TEST
Intervention: The ROC analysis
Description: The Brodsky clinical stage and ultrasonographic data of the participants will be matched, and the diagnostic value of the submental US in the classification of tonsil hypertrophy as non-obstructive and obstructive will be evaluated. A ROC analysis will be used to determine the optimal cut-off value.
Study: NCT04155580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Tablet for oral administration
Study: NCT03223519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comboprofen
Description: Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder for oral solution administered TID for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Powder for oral solution administered TID for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Powder for oral solution administered TID for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Powder for oral solution administered TID for 3 days
Study: NCT04351789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Description: The written and verbal information provided at discharge to patients in the intervention arm will consist of:~An explanation of the normal recovery period after hospitalization due to COVID-19. What can the patient expect physically, psychologically and emotionally, and what coping mechanism might be appropriate Social support in the recovery period and how this can be used constructively. In case of worsening of symptoms - physically or psychologically, where can the patient get help after discharge from hospital.~These points are based on crisis psychology, enhancing the patients empowerment and self-management after discharge from hospital.
Study: NCT01876004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 50 mg/m2, IM (intramuscularly), single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prescribed Placebo IM (intramuscularly), single dose
Study: NCT03233984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sensibilisation program Ma maison, mon environnement santé
Description: The aim of this program is to spread the awarness about endocrine disruptors through workshops and presentation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sensibilisation program Ma maison, mon environnement santé
Description: The aim of this program is to spread the awarness about endocrine disruptors through workshops and presentation.
Study: NCT03338738

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stool culture ans swab
Description: Patients with ESBL enterobacteria, antibiotic pressure are patients with ESBL positive result diagnosed by stool culture and a rectal swab.~The intervention correspond to addition of 4 stool samples (or 4 rectal swabs in the absence of stool emission) and a blood sample.
Study: NCT03463642

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: 100,000IU

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: 100,000IU

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: 100,000IU

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: 100,000IU

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pill
Description: Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pill
Description: Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: orange syrup
Description: 100 drops orange syrup

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: orange syrup
Description: 100 drops orange syrup

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mineral oil
Description: Paraffinum Liquidum,Isopropyl Palmitate,Parfum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mineral oil
Description: Paraffinum Liquidum,Isopropyl Palmitate,Parfum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mineral oil
Description: Paraffinum Liquidum,Isopropyl Palmitate,Parfum

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Penetrator
Description: Tangerine essential oil (10ml)
Study: NCT04496570

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal therapy
Description: Non surgical periodontal therapy was performed to patients with peridontitis
Study: NCT02231099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolift + M
Description: prolapse surgery with mesh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional vaginal prolapse surgery
Description: conventional vaginal prolapse surgery;anterior colporrhaphy, posterior colporrhaphy
Study: NCT03405961

Intervention type: DEVICE
Intervention: Carestream 3600 intra oral scan
Description: Carestream 3600 is CE marked intra oral scanner manufactured by Carestream Dental. It is already licensed for use in dentistry to produce digital study models. The scanner is 220 x 38 x 58 mm large and operates using video capture technology. It emits no radiation.~Carestream 3600 is connected to a computer via a USB port and a computer software (CS Model +) converts the scan into digital study models using trigonometric calculations. The software is then used to take measurements on the digital models and calculate PAR scores

Intervention type: DEVICE
Intervention: Carestream 3600 intra oral scan
Description: Carestream 3600 is CE marked intra oral scanner manufactured by Carestream Dental. It is already licensed for use in dentistry to produce digital study models. The scanner is 220 x 38 x 58 mm large and operates using video capture technology. It emits no radiation.~Carestream 3600 is connected to a computer via a USB port and a computer software (CS Model +) converts the scan into digital study models using trigonometric calculations. The software is then used to take measurements on the digital models and calculate PAR scores
Study: NCT02820948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E ointment application
Description: Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
Study: NCT02460601

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qizhiweitong granule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qizhiweitong granule
Study: NCT03337490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 0.5% Topical Application Lotion
Description: Subjects on Test Product will receive a single dose, 117g, during the study to be applied at baseline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin 0.5% Topical Application Lotion [SKLICE]
Description: Subjects on Reference Product will receive a single dose, 117g, during the study to be applied at baseline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0% Lotion
Description: Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.
Study: NCT04095429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expect Respect
Description: Expect Respect is a 24 session curriculum designed to support middle school students to increase skills in emotion regulation, relationship skills, communication, and positive bystander intervention behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants will be connected via a warm referral to available individual behavioral health supports and resources in their community that can support them.
Study: NCT02292069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/Atorvastatin calcium
Description: Amlodipine besylate/Atorvastatin calcium 10/80 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate/Atorvastatin calcium
Description: Amlodipine besylate/Atorvastatin calcium 10/80 mg
Study: NCT00973713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 10mg/d
Study: NCT01689194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: genexolPM + cisplatin
Study: NCT02859584

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL
Study: NCT00837317

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil, SF, SF+DMP, SF+phenols
Description: All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
Study: NCT03502551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine infusion (0.5 mg/kg) over 40 minutes.
Study: NCT04004871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel, Cisplatin and Fluorouracil
Description: Patients receive Nab-paclitaxel (200mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before concurrent chemoradiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiotherapy
Description: Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
Study: NCT01745497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 3mg/kg liquid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent volume of liquid with similar color and taste.
Study: NCT03033550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief negotiated mobile application
Description: The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
Study: NCT02546700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab 125 milligrams (mg) will be administered subcutaneously once in every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab 125 milligrams (mg) will be administered subcutaneously once in every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously once in every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously once in every 4 weeks.
Study: NCT03238170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scan using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan
Study: NCT04036370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS group
Description: Pecs block performed using ultrasound guidance. Standard pain follow up and monitorization will be performed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Standard pain follow up and monitorization will be performed.
Study: NCT01828151

Intervention type: DEVICE
Intervention: Noninvasive ventilation mask
Study: NCT02470988

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Analysis System of Psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBASP Without DPI
Study: NCT03405233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double vein cuffed ePTFE graft both at the inflow and outflow ends
Description: Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around both ends of PTFE Graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single vein cuffed eTFE graft both at the inflow and outflow ends
Description: Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around the venous end of PTFE Graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ePTFE graft without any cuff
Description: anastmosis between arterial and venous side usinf non cuffed ePTFE graft
Study: NCT01787162

Intervention type: OTHER
Intervention: Echocardiography, spiroergometry, cardiac catheterization
Description: patients with CMPD will undergo echocardiography, spiroergometry, and right heart catheterization, if indicated
Study: NCT02152280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danhong Injection
Description: Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
Study: NCT02619162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Tablets of 100 mg. or 150 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Tablet of 2.5 mg.
Study: NCT03005405

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ionomer Restoration (control)
Description: Restoration of moderate caries lesions after partial caries removal using high viscosity glass ionomer cements

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ionomer Sealant (test)
Description: Sealing of moderate caries lesions without any caries removal or cavity opening.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene orientation and professional fluoride application
Description: Oral hygiene orientation and professional fluoride application

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral hygiene orientation and professional fluoride application
Description: Oral hygiene orientation and professional fluoride application
Study: NCT01782391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: no stimulation
Study: NCT01406613

Intervention type: OTHER
Intervention: Observation
Description: In this study we will examine the changes in bone density by DXA and QUS and bone turnover after stopping Bisphosphonate treatment. As we wish to measure the speed of offset of effects of treatment we have scheduled visits at 24 week intervals in order to fully assess this effect.
Study: NCT03637439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Percutaneous Neuromodulation
Description: It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ultrasound-guided Percutaneous Needle
Description: Same protocol without electricity
Study: NCT02004678

Intervention type: DRUG
Group type: OTHER
Intervention: DS-1150b

Intervention type: DRUG
Group type: OTHER
Intervention: DS-1150b

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study: NCT03152929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: 20-30 mL 0.5% Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pectoral Nerve Block
Description: 20-30 mL 0.5% Ropivacaine
Study: NCT02801812

Intervention type: DEVICE
Intervention: nailfold capillaroscopy
Description: Detection by nailfold capillaroscopy of capillary abnormalities in patients with Systemic Lupus Erythematosus and comparison with healthy controls at enrolment
Study: NCT03509519

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: NMES-Millicurrent
Description: Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min per leg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMES-Millicurrent
Description: Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min per leg.
Study: NCT04421690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants (n=15) will complete computerized cognitive training games and activities online 3 times/week for 8 weeks.
Study: NCT04218851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole IV
Description: Posaconazole (POS) 6 mg/kg body weight by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole PFS
Description: Dosing based on weight-band taken orally
Study: NCT01018810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2525623 Intravenous
Description: administered intravenously at randomization and every 2 weeks for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2525623 Subcutaneous
Description: administered subcutaneously at randomization and every 2 weeks for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2525623 Subcutaneous
Description: administered subcutaneously at randomization and every 2 weeks for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2525623 Subcutaneous
Description: administered subcutaneously at randomization and every 2 weeks for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2525623 Subcutaneous
Description: administered subcutaneously at randomization and every 2 weeks for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intravenous
Description: administered intravenously at randomization and every 2 weeks for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Subcutaneous
Description: administered subcutaneously at randomization and every 2 weeks for 6 weeks
Study: NCT02069860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone Anchored Port System (BAP)
Description: The port body will be implanted onto the petrous bone and a sealing cap, a twofold valve system and a catheter are connected to the port body. The catheter is tunneled under the skin, enters the internal jugular vein and ends in the right atrium of the heart. The novelty of the access lies in its location (retro auricular on petrous bone) and its bone fixation.